U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07055087) titled 'Prevent Cognitive Decline in GBA-associated Parkinson's Disease' on June 03.
Brief Summary: This is a proof-of-concept trial to investigate the efficacy of prasinezumab to slow or prevent cognitive decline in people with Parkinson's disease carrying a severe mutation in the GBA (glucocerebrosidase) gene. The duration of the intervention per patient will be 104 weeks with monthly infusions. The investigators plan to enroll 120 participants (60 participants per treatment arm). This study will be conducted across Europe in the following countries: France, Germany, Italy, Luxembourg, Spain, Sweden, UK.
Study Start Date: Dec., 2025
Stud...